{"id":4010,"date":"2025-03-31T18:11:55","date_gmt":"2025-03-31T18:11:55","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/fondaparinux-sodium-txt\/"},"modified":"2025-03-31T18:11:55","modified_gmt":"2025-03-31T18:11:55","slug":"fondaparinux-sodium-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/fondaparinux-sodium-txt\/","title":{"rendered":"Fondaparinux sodium.txt"},"content":{"rendered":"<h1>  Fondaparinux sodium   <\/h1>\n<p><H3>  CLINICAL USE <\/H3><br \/>\nProphylaxis of deep vein thrombosis Treatment of deep vein thrombosis,  pulmonary embolism, unstable angina and after a myocardial infarction<H3> DOSE IN NORMAL RENAL FUNCTION  <\/H3>Prophylaxis DVT: Surgical: 2.5 mg 6 hours after surgery,  \u2014then 2.5 mg dailyMedical: 2.5 mg daily \u2014Treatment DVT and PE: 100 kg: 10 mg daily \u2014<H3>  PHARMACOKINETICS    <\/H3><LI> Molecular weight &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :1728<\/li>\n<li>  %Protein binding  &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp  &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :97\u201398.6 (to antithrombin)<\/li>\n<li>  %Excreted unchanged in urine &amp;nbsp &amp;nbsp : 64\u201377<\/li>\n<p><LI> Volume of distribution (L\/kg) &amp;nbsp &amp;nbsp &amp;nbsp :0.1\u20130.12<\/li>\n<p><LI>half-life \u2013 normal\/ESRD (hrs)&amp;nbsp &amp;nbsp &amp;nbsp :17\u201321\/72<H3>  DOSE IN RENAL IMPAIRMENT <\/H3> <H4>GFR (mL\/MIN)<\/H4><LI> 20 to 50  &amp;nbsp &amp;nbsp : Prophylactic dose: 1.5 mg daily. See \u2018Other Information\u2019<LI> 10 to 20  &amp;nbsp &amp;nbsp : Reduce dose. <LI> &lt;10 &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp : Reduce dose. <H3> DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES  <\/H3><LI> CAPD  &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp:Unlikely to be dialysed. Dose as in GFR &lt;10 mL\/min<\/p>\n<li> HD &amp;nbsp  &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :Dialysed. Dose as in GFR &lt;10 mL\/min <LI>HDF\/high flux  &amp;nbsp :Dialysed. Dose as in GFR &lt;10 mL\/min <LI>CAV\/VVHD  &amp;nbsp &amp;nbsp &amp;nbsp:Unknown dialysability. Dose as in GFR 10 to 20   mL\/min <H3> IMPORTANT DRUG INTERACTIONS  <\/H3>Potentially hazardous interactions with other drugsIncreased risk of bleeding in combination  with any other drugs that affect coagulation<H3> ADMINISTRATION  <\/H3><H4> Reconstition<\/H4>\u2013<H4>  Route  <\/H4>SC <H4>  Rate of Administration  <\/H4>\u2013<H4>Comments<\/H4>\u2013<H4>  OTHER INFORMATION  <\/H4>In patients with a GFR of 30\u201350 mL\/min  and weight &gt;100 kg, give an initial dose of 10 mg then reduce to 7.5 mg daily for treatment of a DVT; use with cautionManufacturer advises to avoid in severe  renal impairment due to increased risk of bleedingClearance of fondaparinux increases by up  to 20% during haemodialysisHas been used successfully at a dose of  2.5 mg instilled into the dialysis circuit for anticoagulation during dialysis<br \/>\n","protected":false},"excerpt":{"rendered":"<p>Fondaparinux sodium CLINICAL USE Prophylaxis of deep vein thrombosis Treatment<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4010","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4010","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4010"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4010\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4010"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4010"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4010"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}